662138-60-5

Basic information

• Product Name: ETHYL(2,5-DIFLUOROPHENYL)ACETATE
• Synonyms: ETHYL(2,5-DIFLUOROPHENYL)ACETATE;(2,5-Difluorophenyl)acetic acid ethyl ester
• CAS NO: 662138-60-5
• Molecular Formula: C₁₀H₁₀F₂O₂
• Molecular Weight: 200.1820064
• Product Categories: Phenyls & Phenyl-Het;Esters;Phenyls & Phenyl-Het
• Mol File: 662138-60-5.mol

Chemical Properties

• Boiling Point: 224.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• CAS DataBase Reference: ETHYL(2,5-DIFLUOROPHENYL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL(2,5-DIFLUOROPHENYL)ACETATE(662138-60-5)
• EPA Substance Registry System: ETHYL(2,5-DIFLUOROPHENYL)ACETATE(662138-60-5)

Safety Data

• Hazardous Substances Data: 662138-60-5(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 85068-27-5 2,5-difluorophenylacetic acid 

Downstream Products

• 109346-82-9 2-(2,5-difluorophenyl)acetaldehyde 
• 862255-56-9 2-(2,5-difluorophenyl)ethanol 
• 151954-64-2 3-<<4-phenyl>methyl>-5,7-dimethyl-2-ethyl-3H-imidazo<4,5-b>pyridine 
• 151954-62-0 3-<<4-phenyl>methyl>-5,7-dimethyl-2-ethyl-3H-imidazo<4,5-b>pyridine 
• 151954-59-5 3-<<4-phenyl>methyl>-5,7-dimethyl-2-ethyl-3H-imidazo<4,5-b>pyridine 
• 151954-49-3 3-<<4-phenyl>methyl>-5,7-dimethyl-2-ethyl-3H-imidazo<4,5-b>pyridine 
• 151954-42-6 ethyl α-bromo-2,5-difluorophenylacetate 

Relevant articles and documents

2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists

A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.

3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R1, R3, R4 and R5 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Non-Peptide Angiotensin II Receptor Antagonists. 2. Design, Synthesis, and Biological Activity of N-Substituted (Phenylamino)phenylacetic Acids and Acyl Sulfonamides

The design, synthesis, and biological activity of a new class of highly potent non-peptide AII receptor antagonists derived from N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides which exhibit a high selectivity for the AT1 receptor are described.A series of N-substituted (phenylamino)phenylacetic acids (9) and acyl sulfonamides (16) and a tetrazole derivative (19) were synthesized and evaluated in the in vitro AT1 (rabbit aorta) and AT2 (rat midbrain) binding assay.The (phenylamino)phenylacetic acids 9c (AT1 IC50=4 nM, AT2 IC50=0.74 μM), 9d (AT1 IC50=5.3 nM, AT2 IC50=0.49 μM), and 9e (AT1 IC50=5.3 nM, AT2 IC50=0.56 μM) were found to be the most potent AT1-selective AII antagonists in the acid series.Incorporation of various substituents in the central and bottom phenyl rings led to a decrease in the AT1 and AT2 binding affinity of the resulting compounds.Replacement of the carboxylic acid (CO2H) in 9c, 9d, and 9e with the bioisostere acyl sulfonamide (CONHSO2Ph) resulted in a (5-7)-fold increase in the AT1 potency of 16a (AT1 IC50=0.9 nM, AT2 IC50=0.2 μM), 16b (AT1 IC50=1 nM, AT2 IC50=2.9 μM), and 16c (AT1 IC50=0.8 nM, AT2 IC50=0.42 μM) and yielded acyl sulfonamides with subnanomolar AT1 activity.Incorporation of the acyl sulfonamide (CONHSO2Ph) for the CO2H of 9c not only enhanced the AT1 potency but also effected a marked increase in the AT2 potency of 16a (AT2 IC50=0.74 μM of 9c vs 0.2 μM of 16a) and made it the most potent AT2 antagonist in this study.Replacement of the CO2H of 9b with the bioisostere tetrazole resulted in 19 (AT1 IC50=15 nM) with a 2-fold loss in the AT1 and a complete loss in the AT2 binding affinity. (Phenylamino)phenylacetic acid 9c demonstrated good oral activity in AII-infused conscious normotensive rats at an oral dose of 1.0 mg/kg by inhibiting the pressor response for >6 h.Acyl sulfonamides 16a-c displayed excellent in vivo activity by blocking the AII-induced pressor response for >6 h after oral administration in conscious rats at a 3.0 mg/kg dose level.Both acyl sulfonamides 16a and 16c exhibited superior in vivo activity in rats compared to that of (phenylamino)phenylacetic acid 9c.